 |
| 2010 |
August 4: Clinical Phase I Results of GANYMED’s iMAB362 Antibody Demonstrate Excellent Safety Release English | Release German |
| 2008 |
[Open Press Releases 2008]
November 18: GANYMED closes EUR 65 M Financing Round Release English | Release German August 22: Tag der offenen Tür und Firmenbesichtigung im Biotechnikum mit dem Thema "Wie gründe ich ein Technologie-Unternehmen?" Release German |
| 2007 |
[Open Press Releases 2007]
September 18: GANYMED increases Series C Financing in Second Closing to Euro 37.2 Million Release English | Release German April 18: GANYMED raises Euro 33.7 Million in Series C Financing Round Release English | Release German |
| 2006 |
[Open Press Releases 2006]
November 30: Neue Wege gegen den Krebs gehen Release German November 17: Standort gesichert - Ganymed Pharmaceuticals AG bleibt in Mainz Release German October 11: Dr. Thomas M. Rinderknecht chairs Supervisory Board of GANYMED Release English | Release German April 05: GANYMED lead antibodies show excellent efficacy and safety in mouse tumor models Release English | Release German |
| 2005 |
[Open Press Releases 2005]
September 21: GANYMED scientists receive Georges-Köhler Award Release English | Release German August 31: GANYMED and the University of Mainz broaden their successful cooperation in the fight against cancer Release English | Release German July 6: GANYMED raises EUR 14.4 million in Series B Financing Round Release English | Release German |
| 2004 |
[Open Press Releases 2004]
June 8: GANYMED announces license of WT 1 Immunotherapy rights by CORIXA and KIRIN Release English April 26: Genmab licenses cancer target from Ganymed Release English April 1: GANYMED names Rainer Wessel Ph.D. as President & CEO Release English | Release German March 16: New cooperation on Identification of Multiple Sclerosis Pathogens established between GANYMED Pharmaceuticals AG and the University of Rotterdam Release English | Release German |
| 2003 |
[Open Press Releases 2003]
December 1: GANYMED acquires ImmuGenics AG and In-licenses Technology from Imperial College London Release English | Release German November 18: GANYMED extended Research Collaboration with the Cantonal Hospital St. Gallen Release English | Release German November 12: GANYMED names 3 pharmaceutical industry executives to its Supervisory Board Release English | Release German November 11: Ganymed names James A. Ratigan CEO Release English | Release German June 5: Cooperation on Target Validation established between GANYMED Pharmaceuticals AG and the University of Ghent Release English | Release German |
| 2002 |
[Open Press Releases 2002]
December 3: GANYMED Pharmaceuticals AG and Cantonal Hospital St. Gallen cooperate on Chlamydia pneumoniae research Release English | Release German June / Mainz: GANYMED Pharmaceuticals AG secures 8.85 million EUR first-round financing Release English | Release German |
[August 2010]
Clinical Phase I Results of GANYMED’s iMAB362 Antibody Demonstrate Excellent Safety
[April 2010]
ERNST & YOUNG, Deutscher Biotechnologie-Report 2010,
Das "Mainzer Modell": CI3
[Jan 2010]
34. Sendung TV-Magazin „in vivo“: vor Ort im Tumorvakzinationszentrum und bei Ganymed, Mainz (Deutsche Krebshilfe e. V.)
[September 2010]
European Cancer Cluster
Partnering, 15-17 sept. 2010,
(Folketeateret Oslo AS),
Oslo, Norway
[November 2010]
Bio-Europe 2010,
November 15-17, 2010
(International Congress Centre
Munich (ICM))
Association for Cancer Immunotherapy
Biotechnologie-Industrie-Organisation Deutschland e.V.
International Council for the Life Sciences
